Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.

Allarity Therapeutics Inc

ALLR
0,45
-0,0178 (-3,81%)
15 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
06/6/202414:54EDGAR2Form 8-K - Current report
24/5/202414:55EDGAR2Form 8-K/A - Current report: [Amend]
21/5/202414:15EDGAR2Form 8-K - Current report
20/5/202414:00GLOBEAllarity Therapeutics Regains Compliance with Nasdaq's..
17/5/202422:08EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15/5/202415:15EDGAR2Form 8-K - Current report
14/5/202422:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202422:01GLOBEAllarity Therapeutics Reports First Quarter Financial..
09/5/202417:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09/5/202415:47EDGAR2Form 8-K - Current report
08/5/202422:05EDGAR2Form RW - Registration Withdrawal Request
07/5/202415:30GLOBEAllarity Therapeutics Announces that All Series A Preferred..
06/5/202415:29EDGAR2Form 8-K - Current report
06/5/202415:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/5/202414:00GLOBEAllarity Therapeutics Exceeds Nasdaq’s Minimum Equity..
02/5/202414:00GLOBEAllarity Therapeutics’ Stenoparib Shows Clear Clinical..
29/4/202413:00GLOBEAllarity Therapeutics Regains Compliance with NASDAQ Minimum..
17/4/202415:10GLOBEAllarity Therapeutics Receives NASDAQ-Approved Extension to..
04/4/202415:15GLOBEAllarity Therapeutics Announces 1-for-20 Reverse Stock Split
27/3/202413:30GLOBEAllarity Therapeutics Makes Strategic Pivot to Focus Solely..
25/3/202412:30GLOBEAllarity Therapeutics Receives Extension from Nasdaq..
08/3/202414:38EDGAR2Form 8-K - Current report
08/3/202413:15EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08/3/202413:15GLOBEAllarity Therapeutics Reports Full Year 2023 Financial..
08/3/202403:45EDGAR2Form DEF 14A - Other definitive proxy statements
04/3/202422:05EDGAR2Form 8-K - Current report
01/3/202415:21EDGAR2Form 8-K - Current report
28/2/202412:00GLOBEAllarity Therapeutics to Present at Biomarkers 2024
23/2/202422:09EDGAR2Form PRER14A - Preliminary Proxy Soliciting materials
14/2/202415:03EDGAR2Form 8-K - Current report
02/2/202423:03EDGAR2Form D - Notice of Exempt Offering of Securities
01/2/202422:40EDGAR2Form 8-K - Current report
26/1/202423:07EDGAR2Form PRE 14A - Other preliminary proxy statements
25/1/202423:24EDGAR2Form 8-K - Current report
19/1/202423:29EDGAR2Form 8-K - Current report
15/12/202323:00EDGAR2Form S-1/A - General form for registration of securities..
12/12/202312:00GLOBEAllarity Therapeutics Announces Thomas Jensen as Interim CEO..
11/12/202312:30EDGAR2Form 8-K - Current report
06/12/202323:00EDGAR2Form 8-K - Current report
06/12/202314:30EDGAR2Form S-1/A - General form for registration of securities..
05/12/202313:30EDGAR2Form 8-K - Current report
05/12/202313:30GLOBEAllarity’s Early Phase 2 Stenoparib Data Indicates Clinical..
17/11/202323:01EDGAR2Form 8-K - Current report
13/11/202314:35EDGAR2Form 8-K - Current report
02/11/202322:00EDGAR2Form S-3 - Registration statement under Securities Act of..
31/10/202314:30EDGAR2Form S-1 - General form for registration of securities under..
30/10/202322:00EDGAR2Form 8-K - Current report
23/10/202323:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
17/10/202323:00EDGAR2Form S-3/A - Registration statement under Securities Act of..
10/10/202323:00EDGAR2Form S-3 - Registration statement under Securities Act of..
Apertura: 0,47 Min: 0,438 Max: 0,48
Chiusura: 0,4678

La tua Cronologia

Delayed Upgrade Clock

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network